Time to make an impact

Publish your research, make change

Taylor & Francis welcomes a broad range of research submissions pertaining to RNA and Vaccine Development.

Contribute your impact and make real world change by publishing in any of our top journals.

As always we look forward to pushing scientific boundaries, and fostering human progress through knowledge.

“Realization of the much-heralded advent of RNA vaccines with the successful mass treatment of COVID-19 arguably begins to draw down the second age of (recombinant) vaccines and opens the way for a plethora of new prophylactics and immunotherapy for previously intractable, virulent infections as diverse as gastric carcinoma and malaria. This third generation of new RNA vaccines are identified by reverse vaccinology; genomics led, forged at the interface of pathogen biology and RNA technology, and seasoned in the real word experience of clinical trials.”
Kevin Tyler, Editor in Chief; Virulence

Open Access Journal
Go to
Journal metrics
Latest articles
Author Instructions

Research in action

Coronavirus disease 2019—Historical context, virology, pathogenesis, immunotherapy, and vaccine development

The current Coronavirus Disease 2019 (COVID-19) pandemic is causing great alarm around the world. The pathogen for COVID-19 – severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

RNA has been increasingly recognized as the central molecule in all life with new functions uncovered by the year. With the unfolding of the Covid-19 pandemic, RNA has forcefully entered the field of biomedicine. RNA-based Covid-19 vaccines were spectacularly successful in helping to bring the pandemic under control, thus providing further impetus to developing additional RNA vaccines for both infectious diseases and cancer
-Ron Ellis (Human Vaccines EiC) and Adam Weiss (Acquisitions Editor for Human Vaccines, Virulence, and RNA Biology), February 2023

Making an Impact

Hepatitis B vaccine development and implementation

Vaccination against hepatitis B is the most effective strategy to control HBV infection. The first licensed hepatitis B vaccine was developed by the purification of hepatitis B surface antigen (HBsAg) from plasma of asymptomatic HBsAg carriers. Then, the recombinant

Open Access Journal
Go to
Journal metrics
Latest articles
Author Instructions

Allows Open Access Submissions
Go to
Journal metrics
Latest articles
Author Instructions

Your Research, Your Impact

Check out the latest research from our top journals in the RNA and Vaccine Development sections.

In 2017, the World Health Organization (WHO) named A. baumannii as one of the three antibiotic-resistant bacterial species on its list of global priority pathogens in dire need of novel and effective treatment. With only polymyxin and tigecycline antibiotics left as last-resort treatments, the need for novel alternative approaches to the control of this bacterium becomes imperative.

Full Article

Invasive non-typhoidal Salmonella (iNTS) infections are a leading cause of bacteremia in Sub-Saharan Africa (sSA), thereby representing a major public health threat. Salmonella Typhimurium clade ST313 and Salmonella Enteriditis lineages associated with Western and Central/Eastern Africa are among the iNTS serovars which are of the greatest concern due to their case-fatality rate, especially in children and in the immunocompromised population.

Full Article

African swine fever (ASF) is a lethal and highly contagious viral disease of domestic and wild pigs, listed as a notifiable disease reported to the World Organization for Animal Health (OIE). Despite its limited host range and absent zoonotic potential, the socio-economic and environmental impact of ASF is very high, representing a serious threat to the global swine industry and the many stakeholders involved.

Full Article

There are currently no effective treatments for Methamphetamine (METH) addiction and psychotherapy remains the sole treatment option. The development of immunopharmacotherapies for the treatment of drug addiction, overdose, and relapse management appears to be promising alternative and a significant body of information has been generated using various vaccine development strategies.

Full Article

Vaccines are a major achievement in medical sciences, but the development of more effective vaccines against infectious diseases is essential for prevention and control of emerging pathogens worldwide. The application of omics technologies has advanced vaccinology through the characterization of host-vector-pathogen molecular interactions and the identification of candidate protective antigens.

Full Article

Time to make an impact

Publish your research, make change

Your Research, Your Impact

Facing the challenges of multidrug-resistant Acinetobacter baumannii: progress and prospects in the vaccine development

Pathogenic signature of invasive non-typhoidal Salmonella in Africa: implications for vaccine development

African swine fever control and prevention: an update on vaccine development

Vaccine development against methamphetamine drug addiction

Vaccinomics: a future avenue for vaccine development against emerging pathogens